Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 366

1.

Tumefactive inflammatory leukoencephalopathy in cocaine users: Report of three cases.

Pessini LM, Kremer S, Auger C, Castilló J, Pottecher J, de Sèze J, Lhermitte B, Maciag E, Rovira A.

Mult Scler Relat Disord. 2019 Nov 4;38:101496. doi: 10.1016/j.msard.2019.101496. [Epub ahead of print]

PMID:
31707217
2.

Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis.

Vermersch P, De Sèze J, Clavelou P, Durand-Dubief F, Maillart E, Mekies C, Moreau T, Papeix C, Tourbah A, Labauge P.

Mult Scler Relat Disord. 2019 Sep 19;36:101406. doi: 10.1016/j.msard.2019.101406. [Epub ahead of print]

PMID:
31563076
3.

MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests.

Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Mayran P, Bieuvelet S, Vallée M, Bertillot F, Klaeylé L, Argoud AL, Zinaï S, Tourbah A.

Eur J Neurol. 2019 Sep 20. doi: 10.1111/ene.14091. [Epub ahead of print]

PMID:
31538396
4.

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA; OFSEP Investigators.

JAMA Neurol. 2019 Sep 3. doi: 10.1001/jamaneurol.2019.2670. [Epub ahead of print]

PMID:
31479149
5.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

6.

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease.

Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Deschamps R, Solà-Valls N, Llufriu S, De Seze J, Blanco Y, Vukusic S, Saiz A, Marignier R.

J Neuroinflammation. 2019 Jul 2;16(1):134. doi: 10.1186/s12974-019-1525-1.

7.

Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra.

El Khoury Y, Collongues N, De Sèze J, Gulsari V, Patte-Mensah C, Marcou G, Varnek A, Mensah-Nyagan AG, Hellwig P.

Analyst. 2019 Aug 7;144(15):4647-4652. doi: 10.1039/c9an00754g. Epub 2019 Jul 1.

PMID:
31257384
8.

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group.

Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24.

9.

Editorial.

Thouvenot É, de Seze J.

Rev Neurol (Paris). 2019 Jun;175(6):339-340. doi: 10.1016/j.neurol.2019.04.002. Epub 2019 May 12. No abstract available.

PMID:
31088691
10.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
11.

Miller Fisher syndrome mimicking botulism: Clinical and pathophysiological discussion of a case.

Bigaut K, Kremer L, Hacquard A, Collongues N, De Seze J.

Rev Neurol (Paris). 2019 Jun;175(6):403-405. doi: 10.1016/j.neurol.2018.06.012. Epub 2019 Apr 30. No abstract available.

PMID:
31047688
12.

Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.

Ayrignac X, Rigau V, Lhermitte B, Vincent T, de Champfleur NM, Carra-Dalliere C, Charif M, Collongues N, de Seze J, Hebbadj S, Ahle G, Oesterlé H, Cotton F, Durand-Dubief F, Marignier R, Vukusic S, Taithe F, Cohen M, Guennoc AM, Kerbrat A, Edan G, Carsin-Nicol B, Allou T, Sablot D, Thouvenot E, Ruet A, Magy L, Boncoeur-Martel MP, Labauge P, Kremer S.

J Neurol. 2019 Jul;266(7):1743-1755. doi: 10.1007/s00415-019-09328-7. Epub 2019 Apr 23.

PMID:
31016376
13.

Emotional disturbances in multiple sclerosis: A neuropsychological and fMRI study.

Pfaff L, Lamy J, Noblet V, Gounot D, Chanson JB, de Seze J, Blanc F.

Cortex. 2019 Aug;117:205-216. doi: 10.1016/j.cortex.2019.02.017. Epub 2019 Mar 1.

PMID:
30991308
14.

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.

Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.

15.

A case of acute posterior multifocal placoid pigment epitheliopathy with aseptic meningitis and cerebral infarction.

Bigaut K, Kremer L, Hacquard A, Wolff B, Collongues N, De Seze J.

Rev Neurol (Paris). 2019 May;175(5):329-331. doi: 10.1016/j.neurol.2018.06.011. Epub 2019 Mar 28. No abstract available.

PMID:
30928157
16.

Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome.

Makhani N, Lebrun C, Siva A, Narula S, Wassmer E, Brassat D, Brenton JN, Cabre P, Carra Dallière C, de Seze J, Durand Dubief F, Inglese M, Langille M, Mathey G, Neuteboom RF, Pelletier J, Pohl D, Reich DS, Ignacio Rojas J, Shabanova V, Shapiro ED, Stone RT, Tenembaum S, Tintoré M, Uygunoglu U, Vargas W, Venkateswaren S, Vermersch P, Kantarci O, Okuda DT, Pelletier D; Observatoire Francophone de la Sclérose en Plaques (OFSEP), Société Francophone de la Sclérose en Plaques (SFSEP), the Radiologically Isolated Syndrome Consortium (RISC) and the Pediatric Radiologically Isolated Syndrome Consortium (PARIS).

Mult Scler J Exp Transl Clin. 2019 Mar 20;5(1):2055217319836664. doi: 10.1177/2055217319836664. eCollection 2019 Jan-Mar.

17.

FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis.

Kremer L, Taleb O, Boehm N, Mensah-Nyagan AG, Trifilieff E, de Seze J, Brun S.

J Neuroinflammation. 2019 Mar 2;16(1):54. doi: 10.1186/s12974-019-1441-4.

18.

[Retrobulbar optic neuritis in a 15-year-old boy].

Taleb A, De Sèze J, Speeg-Schatz C, Sauer A.

J Fr Ophtalmol. 2019 Mar;42(3):336-340. doi: 10.1016/j.jfo.2018.06.017. Epub 2019 Feb 21. French. No abstract available.

PMID:
30797569
19.

Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Apr;266(4):816. doi: 10.1007/s00415-019-09215-1.

PMID:
30759286
20.

Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD).

Bigaut K, Achard S, Hemmert C, Baloglu S, Kremer L, Collongues N, De Sèze J, Kremer S.

PLoS One. 2019 Jan 29;14(1):e0211465. doi: 10.1371/journal.pone.0211465. eCollection 2019.

21.

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C.

Mult Scler Relat Disord. 2019 Apr;29:7-14. doi: 10.1016/j.msard.2019.01.019. Epub 2019 Jan 6.

PMID:
30654246
22.

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options.

Collongues N, Ayme-Dietrich E, Monassier L, de Seze J.

Drugs. 2019 Feb;79(2):125-142. doi: 10.1007/s40265-018-1039-7. Review.

PMID:
30623348
23.

Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Apr;266(4):806-815. doi: 10.1007/s00415-018-9160-9. Epub 2019 Jan 3. Erratum in: J Neurol. 2019 Feb 7;:.

PMID:
30607536
24.

Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases.

Codjia P, Ayrignac X, Carra-Dalliere C, Cohen M, Charif M, Lippi A, Collongues N, Corti L, De Seze J, Lebrun C, Vukusic S, Durand-Dubief F, Labauge P; SFSEP and OFSEP.

Mult Scler Relat Disord. 2019 Feb;28:109-116. doi: 10.1016/j.msard.2018.12.022. Epub 2018 Dec 18.

PMID:
30592992
25.

Ocrelizumab for the treatment of multiple sclerosis.

Bigaut K, De Seze J, Collongues N.

Expert Rev Neurother. 2019 Feb;19(2):97-108. doi: 10.1080/14737175.2019.1561284. Epub 2018 Dec 28.

PMID:
30570368
26.

Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.

de Seze J.

Curr Opin Neurol. 2019 Feb;32(1):111-114. doi: 10.1097/WCO.0000000000000650. Review.

PMID:
30562266
27.

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M; the OFSEP Investigators.

Mult Scler. 2018 Dec 13:1352458518815602. doi: 10.1177/1352458518815602. [Epub ahead of print]

PMID:
30541380
28.

Measurement of magnetization transfer ratio (MTR) from cervical spinal cord: Multicenter reproducibility and variability.

Combès B, Monteau L, Bannier E, Callot V, Labauge P, Ayrignac X, Carra Dallière C, Pelletier J, Maarouf A, de Seze J, Collongues N, Barillot C, Edan G, Ferré JC, Kerbrat A; EMISEP study group.

J Magn Reson Imaging. 2019 Jun;49(6):1777-1785. doi: 10.1002/jmri.26537. Epub 2018 Oct 22.

PMID:
30350328
29.

Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.

Ungureanu A, de Seze J, Ahle G, Sellal F.

Rev Neurol (Paris). 2018 Dec;174(10):675-679. doi: 10.1016/j.neurol.2018.01.378. Epub 2018 Oct 4. Review.

PMID:
30293882
30.

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt. 2018 Dec;89(12):1388-1399. doi: 10.1007/s00115-018-0607-0. Review. German.

PMID:
30264269
31.

Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study.

Defer G, de Seze J, Bouee S, Courouve L, Longin J, Payet M, Deleglise ASJ; study group.

Mult Scler Relat Disord. 2018 Oct;25:276-281. doi: 10.1016/j.msard.2018.08.004. Epub 2018 Aug 6.

PMID:
30170267
32.

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S; Société Francophone de la Sclérose en Plaques.

J Neurol. 2018 Oct;265(10):2251-2259. doi: 10.1007/s00415-018-8984-7. Epub 2018 Jul 27.

PMID:
30054790
33.

Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?

Fitsiori A, Fornecker LM, Simon L, Karentzos A, Galanaud D, Outteryck O, Vermersch P, Pruvo JP, Gerardin E, Lebrun-Frenay C, Lafitte F, Cottier JP, Clerc C, de Seze J, Dietemann JL, Kremer S.

Eur Radiol. 2019 Jan;29(1):102-114. doi: 10.1007/s00330-018-5543-7. Epub 2018 Jun 19.

PMID:
29922935
34.

Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.

Combès B, Kerbrat A, Ferré JC, Callot V, Maranzano J, Badji A, Le Page E, Labauge P, Ayrignac X, Carra Dallière C, de Champfleur NM, Pelletier J, Maarouf A, de Seze J, Collongues N, Brassat D, Durand-Dubief F, Barillot C, Bannier E, Edan G.

Mult Scler. 2019 Jul;25(8):1113-1123. doi: 10.1177/1352458518781999. Epub 2018 Jun 18.

PMID:
29909771
35.

Demyelinating diseases.

Lebrun C, de Seze J.

Rev Neurol (Paris). 2018 Jun;174(6):355. doi: 10.1016/j.neurol.2018.04.007. No abstract available.

PMID:
29903398
36.

An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies.

Brun S, Schall N, Bonam SR, Bigaut K, Mensah-Nyagan AG, de Sèze J, Muller S.

J Autoimmun. 2018 Aug;92:114-125. doi: 10.1016/j.jaut.2018.05.009. Epub 2018 Jun 5.

PMID:
29884340
37.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

38.

Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics.

Collongues N, Patte-Mensah C, De Seze J, Mensah-Nyagan AG, Derfuss T.

Expert Rev Neurother. 2018 Jun;18(6):515-522. doi: 10.1080/14737175.2018.1481390. Epub 2018 Jun 6. Review.

PMID:
29799288
39.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

40.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
41.

The effect of oxysterols on nerve impulses.

Bezine M, Namsi A, Sghaier R, Ben Khalifa R, Hamdouni H, Brahmi F, Badreddine I, Mihoubi W, Nury T, Vejux A, Zarrouk A, de Sèze J, Moreau T, Nasser B, Lizard G.

Biochimie. 2018 Oct;153:46-51. doi: 10.1016/j.biochi.2018.04.013. Epub 2018 Apr 21. Review.

PMID:
29684511
42.

Late activity rebound in non-active multiple sclerosis: A rare event.

Corti L, Ayrignac X, Carra Dalliere C, Charif M, de Sèze J, Biotti D, Ciron J, Labauge P.

Mult Scler. 2018 Oct;24(12):1649-1650. doi: 10.1177/1352458518765670. Epub 2018 Mar 13. No abstract available.

PMID:
29533160
43.

FDG PET and MRI Findings in a Case of Bing-Neel Syndrome.

Bund C, Lhermitte B, De Seze J, Kremer S, Namer IJ.

Clin Nucl Med. 2018 Apr;43(4):262-264. doi: 10.1097/RLU.0000000000002019.

PMID:
29465488
44.

Modulation of Kv3.1b potassium channel level and intracellular potassium concentration in 158N murine oligodendrocytes and BV-2 murine microglial cells treated with 7-ketocholesterol, 24S-hydroxycholesterol or tetracosanoic acid (C24:0).

Bezine M, Maatoug S, Ben Khalifa R, Debbabi M, Zarrouk A, Wang Y, Griffiths WJ, Nury T, Samadi M, Vejux A, de Sèze J, Moreau T, Kharrat R, El Ayeb M, Lizard G.

Biochimie. 2018 Oct;153:56-69. doi: 10.1016/j.biochi.2018.02.008. Epub 2018 Feb 17.

PMID:
29462682
45.

Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses.

Jeanjean M, Bind MA, Roux J, Ongagna JC, de Sèze J, Bard D, Leray E.

Environ Res. 2018 May;163:43-52. doi: 10.1016/j.envres.2018.01.040. Epub 2018 Feb 6.

46.

Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy.

Collongues N, Samama B, Schmidt-Mutter C, Chamard-Witkowski L, Debouverie M, Chanson JB, Antal MC, Benardais K, de Seze J, Velten M, Boehm N.

PLoS One. 2018 Jan 25;13(1):e0191614. doi: 10.1371/journal.pone.0191614. eCollection 2018.

47.

Metabolomics approaches in experimental allergic encephalomyelitis.

Battini S, Bund C, Moussallieh FM, Çiçek AE, De Sèze J, Namer IJ.

J Neuroimmunol. 2018 Jan 15;314:94-100. doi: 10.1016/j.jneuroim.2017.11.018. Epub 2017 Dec 2.

PMID:
29224959
48.

MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?

de Seze J.

Brain. 2017 Dec 1;140(12):3072-3075. doi: 10.1093/brain/awx292. No abstract available.

PMID:
29194504
49.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
50.

Is the Choosing Wisely® campaign model applicable to the management of multiple sclerosis in France? A GRESEP pilot study.

Trumbic B, Zéphir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, de Sèze J.

Rev Neurol (Paris). 2018 Jan - Feb;174(1-2):28-35. doi: 10.1016/j.neurol.2017.06.016. Epub 2017 Nov 8.

PMID:
29128151

Supplemental Content

Loading ...
Support Center